Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 82INDUSTRY 5NIH 2OTHER_GOV 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Dermatologic 1

Conditions

Breast Neoplasms 513Neoplasms 381Lymphoma 341Prostatic Neoplasms 291Melanoma 284Carcinoma, Non-Small-Cell Lung 278Precursor Cell Lymphoblastic Leukemia-Lymphoma 264Lung Neoplasms 257Leukemia, Lymphocytic, Chronic, B-Cell 249Leukemia, Myeloid, Acute 236Leukemia 235Lymphoma, Non-Hodgkin 227Colonic Neoplasms 226Ovarian Neoplasms 208Lymphoma, Large B-Cell, Diffuse 208Multiple Myeloma 207Brain Neoplasms 206Colorectal Neoplasms 203Lymphoma, Follicular 201Rectal Neoplasms 194Burkitt Lymphoma 183Neoplasm Metastasis 180Carcinoma, Renal Cell 172Glioblastoma 169Sarcoma 168Lymphoma, Mantle-Cell 166Pancreatic Neoplasms 158Lymphoma, B-Cell, Marginal Zone 145Unspecified Adult Solid Tumor, Protocol Specific 141Hodgkin Disease 141

Interventions

Clonidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Neoplasms, Second Primary × Clear all
NCT00342797 2024-03-07

Retinoblastoma Biomarker Study

National Institutes of Health Clinical Center (CC)

Completed
2,136 enrolled
DermatologicOther solid neoplasmSarcoma

Melanoma, Retinoblastoma, Sarcoma, Neoplasms, Second Primary

NCT00166686 2013-01-11

Clonidine for Neurocognitive Sequelae

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Phase 1/2 Withdrawn
Tumor-Agnostic

Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡